ConcertAI

Genomic testing plays a crucial role in enhancing our understanding of tumors by uncovering key details like molecular variants, fusions, and copy number abnormalities. These mutation profiles are especially valuable when comparing specimens before and after specific lines of therapy to track changes in tumor cells, including the development of resistant populations. By collaborating with innovative clinical laboratories and technology leaders, we can combine our data with various sources like radiological images, digital pathology, whole transcriptome/whole exam/whole slide images, longitudinal liquid biopsies, and comprehensive monitoring of hematological malignancies. Learn more about Genome360™: https://hubs.ly/Q02GPvFN0 #GenomicTesting #TranslationalSciences #DataPartnerships #InnovativeTherapies #ResearchCollaboration

Ensuring that all patients have access to high-quality oncology care is crucial for the health and well-being of our communities. In our latest blog post, we dive into the recent proposed rule changes by the Centers for Medicare & Medicaid Services for 2025 and how they could impact oncology practices. The proposed changes could result in a 5 to 6% decrease in reimbursement for oncology care, on top of higher costs for delivering those services. This could have a significant impact on the ability of healthcare providers to invest in the latest medical innovations and provide equitable care to all patients. That's why organizations like the American Society of Clinical Oncology are supporting legislation like H.R. 2474, which would provide a permanent, annual reimbursement update to help practices stay ahead of the curve and continue delivering top-notch care to patients. Check out our blog post for more insights on this important issue: https://hubs.ly/Q02GpqZh0 #oncology #healthcare #patientcare #Medicare #blogpost #communitycare

Every patient’s cancer journey is unique, but they all share one commonality: the hope for a better outcome. At ConcertAI, we are committed to transforming that hope into a reality by harnessing the power of real-world data and artificial intelligence. Our RWD360 platform combines electronic medical records, medical claims, physician notes, and more to provide the broadest view of solid tumors and hematological malignancies. By analyzing this diverse set of data sources, we can better understand treatments, surgeries, laboratory values, and response criteria. With our Patient360 curated data, we are able to dive deeper into specific details such as lines of therapy, disease progression, and outcomes. This allows us to provide more comprehensive and personalized insights for physicians and patients alike. Through our NLP360 technology, we are able to extract even more clinically relevant oncology information from our data resources using natural language processing and AI. This helps us stay at the forefront of data curation and analysis in the field of cancer research and clinical development. Join us on this journey towards better outcomes for all cancer patients! Learn more about our Real-World Data Products: https://hubs.ly/Q02GgCR-0 #RWD360 #PatientJourney #CancerResearch #AIInHealthcare

Say goodbye to redundant tasks and streamline your data flow from Electronic Medical Record to Electronic Data Capture systems with this integrated software. EMR2EDC pre-populates eCRFs, simplifies data verification, and consolidates patient data management all in one place. The user-friendly software makes day-to-day operations a breeze for clinical research staff. Want to learn more about how EMR2EDC can revolutionize your research process? Request to download our factsheet: https://hubs.ly/Q02FRn0Y0 #ClinicalResearch #EMR2EDC #DataManagement #Efficiency #Innovation

Powered by ConcertAI’s Digital Trial Solutions, learn how TriaLinQ a secure, AI-driven platform enhances efficiency, ensures compliance, and accelerates every phase of the clinical trial process, from patient recruitment to data management. Request to download the factsheet to learn more about how TriaLinQ can benefit your practice: https://hubs.ly/Q02FdV0v0 #clinicaltrials #oncology #AI #digitalhealth #innovation

Curious about natural history studies in oncology? Watch Jennifer R. Rider, ScD, MPH, ConcertAI's Vice President of Real World Evidence Services, explain why ConcertAI's curated data is well suited for conducting natural history studies among patients diagnosed with solid and hematologic malignancies. Learn more about our real-world data products: https://hubs.ly/Q02F7kmQ0 #RealWorldEvidence #CancerResearch #DataScience

Gilead Sciences has recently published a manuscript in Breast Cancer Research and Treatment, shedding light on the real-world use patterns, effectiveness, and tolerability of Sacituzumab govitecan (SG) for patients with metastatic triple-negative breast cancer (mTNBC) in the United States. This study included 230 diverse patients using ConcertAI's Patient360™ custom curation database. SG, along with G-CSF, was common in treatment. These findings support SG as a second-line treatment for mTNBC and the data from this study reinforce the positive outcomes seen in clinical trials, providing hope for patients facing this challenging diagnosis. Read manuscript: https://hubs.ly/Q02DW-NL0 #BreastCancerResearch #SGTreatment #MetastaticTNBC #GileadResearch #Patient360

June is National Cancer Survivor Month! Let's take a moment to honor the incredible courage and resilience of over 18 million cancer survivors in the US. Let's stand together and show our support for those fighting the toughest battle of their lives We also want to extend our gratitude to our dedicated team and colleagues who work tirelessly to support cancer patients every day. At ConcertAI, we are proud to provide the largest oncology Real World Data (RWD) in the United States and have a global presence. Our team is committed to conducting research and analyzing data to improve outcomes for cancer patients worldwide. Through our ERACE program, we strive to enhance equality in cancer care, and our cutting-edge insights help drive advancements in the field. We do this work because we are passionate about making a difference in the lives of patients and because we believe in celebrating more survivors in the years to come. Join us in our fight against cancer and learn more about our mission at https://hubs.ly/Q02DxSqB0. Together, we can make a difference. #NationalCancerSurvivorMonth #ConcertAI #FightAgainstCancer

Looking to boost patient counts in a key population while maintaining robust data collection? Look no further than our Patient360™ FAST Registry! Check out our factsheet to learn more about this efficient and cost-effective solution and see how it can benefit your practice. Request your copy here: https://hubs.ly/Q02Dy3tX0 #Patient360 #HealthcareInnovation #DataDrivenHealthcare

Congratulations to Gene Ray, Mark S. Walker, Claudio D’Ambrosio, and the co-authors on the publication of their manuscript "Comparing prospectively assigned trial and real-world lung cancer patients" in the Journal of Comparative Effectiveness Research! This study evaluated the comparability of a clinical trial cohort with a real-world cohort using electronic medical records data. The results suggest that survival patterns between these two groups in the NSCLC setting are not statistically significantly different. Read more: https://hubs.ly/Q02DjR_v0 #lungcancer #research #medicaldata #congratulations #ComparativeEffectivenessResearch